LATITUDE BUT NOT SEASON OF INITIATION PREDICTS CLINICAL RESPONSE TO TNF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE BSR BIOLOGICS REGISTER-RA

LATITUDE BUT NOT SEASON OF INITIATION PREDICTS CLINICAL RESPONSE TO TNF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE BSR BIOLOGICS REGISTER-RA

Bibliographic Details
Main Authors:	Javaid, M, Batra, R, Chana, J, Round, G, Judge, A, Taylor, P, Patel, S, Cooper, C
Format:	Conference item
Published:	2013

Similar Items

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
by: Ding, T, et al.
Published: (2010)

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
by: Bukhari, M, et al.
Published: (2011)

The value of a biologics clinic: Adherence to the BSR guidelines for the use of anti-TNF alpha therapy in rheumatoid arthritis
by: MacDougall-Davis, S, et al.
Published: (2008)

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
by: Deighton, C, et al.
Published: (2010)

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
by: Deighton, C, et al.
Published: (2010)

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
by: Hawley, S, et al.
Published: (2019)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
by: Maini, R, et al.
Published: (1995)

20th anniversary of TNF inhibitors in rheumatoid arthritis
by: Taylor, P
Published: (2019)

T cell genetics and rheumatoid arthritis (RA)
by: Wordsworth, P
Published: (1998)

JAK ACADEMY in Rheumatoid Arthritis (RA)
by: Roberto Caporali, et al.
Published: (2018-09-01)

Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases.
by: Taylor, P
Published: (2001)

ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
by: Feldmann, M, et al.
Published: (2011)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
by: Maini, R, et al.
Published: (1993)

Bone turnover in early rheumatoid arthritis (RA)
by: Sambrook, P, et al.
Published: (1985)

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy (vol 49, pg 1197, 2010)
by: Deighton, C, et al.
Published: (2010)

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.
by: Taylor, P
Published: (2010)

INNOVATIVE TRAINING IN BSR – THE AIMS AND TASKS IN MASTER BSR PROJECT
by: Marzena Grzesiak, et al.
Published: (2018-04-01)

Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
by: Humby, F, et al.
Published: (2022)

Development of anti-TNF therapy for rheumatoid arthritis.
by: Feldmann, M
Published: (2002)

Targeting TNF alpha for the therapy of rheumatoid arthritis.
by: Maini, R, et al.
Published: (1994)

Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
by: Frances Humby, et al.
Published: (2022-08-01)

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
by: Taylor, P, et al.
Published: (2009)

S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils
by: Adéla Navrátilová, et al.
Published: (2021-03-01)

Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.
by: Taylor, P, et al.
Published: (2000)

Rheumatoid arthritis: RA-lowering cardiovascular risk with statins
by: Lee, J, et al.
Published: (2010)

Rheumatoid arthritis: RA--lowering cardiovascular risk with statins.
by: Lee, J, et al.
Published: (2010)

Biologics in rheumatoid arthritis (RA) – recommendations for Swiss practice
by: BA Michel
Published: (2011-05-01)

Adenosine Deaminase (ADA) in Rheumatoid Arthritis in patients (RA)
by: Huda Th. Al-Marsomi
Published: (2009-07-01)

IL-1Ra: its role in rheumatoid arthritis
by: M. Cutolo
Published: (2011-09-01)

Immune, metabolism and therapeutic targets in RA (Rheumatoid Arthritis)
by: Liu Keying
Published: (2022-01-01)

TNF, SOLUBLE RECEPTORS AND AUTOANTIBODIES TO TNF OF PATIENTS WITH RHEUMATOID ARTHRITIS AND HEALTHY DONORS
by: E. A. Golikova, et al.
Published: (2012-05-01)

Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy.
by: Maini, R, et al.
Published: (2000)

Digitalization of BSR in the recession
by: Ekaterina Chytilová, et al.
Published: (2024-01-01)

Are TNF inhibitors still the agent of choice for RA?
by: Taylor, PC
Published: (2023)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
by: Taylor, P, et al.
Published: (2022)

TNF alpha is an effective therapeutic target for rheumatoid arthritis.
by: Feldmann, M, et al.
Published: (1995)

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.
by: Maini, R, et al.
Published: (1997)

The association of extended TNF haplotypes and susceptibility to rheumatoid arthritis
by: Newton, J, et al.
Published: (2001)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
by: Feldmann, M, et al.
Published: (2001)

TNFα - A pivotal role in rheumatoid arthritis?
by: Brennan, F, et al.
Published: (1992)